路透社5月28日 - 药物开发商iTeos Therapeutics ITOS.O周三表示，它计划结束运营并探索出售其资产，包括实验性癌症治疗药物和一个肥胖症项目。
本月早些时候，英国葛兰素史克公司GSK.L和iTeos Therapeutics公司表示，它们已停止开发 (link)，因为在两项研究中，实验性肺癌药物belrestotug未能阻止病情发展。
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.